COMBINATION THERAPY AGENT FOR TREATING RHINITIS

摘要

The invention relates to the use of pantothenol (dexpanthenol) or the physiologically acceptable esters thereof and of pantothenic acid or the physiologically acceptable salts thereof for reducing the undesired systemic resorption of imidazoline-based alpha-sympathomimetics during their topical, in particular nasal, preferably intranasal application in the treatment of rhinitis.